Physician profile
James E Ratliff
NPI 1205892965
$19,030.74
in general payments reported to CMS, 2019-2025
50 companies · $2,723 in 2025
The $2,723 reported for 2025 was more than what 85% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,643 · 2020: $1,542 · 2021: $2,859 · 2022: $3,332 · 2023: $3,114 · 2024: $2,819 · 2025: $2,723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,656.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,655.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $2,530.74 | 2019-2025 | Provenge |
| Bayer Healthcare Pharmaceuticals INC. | $1,504.01 | 2019-2025 | |
| Janssen Biotech, INC. | $1,462.35 | 2019-2025 | Erleada, Akeega |
| Pfizer INC. | $1,252.92 | 2019-2025 | |
| Astellas Pharma US INC | $1,229.46 | 2019-2025 | Xtandi |
| Blue Earth Diagnostics | $1,210.17 | 2019-2025 | Posluma |
| Sumitomo Pharma America, INC. | $1,151.89 | 2023-2025 | Gemtesa, Orgovyx |
| Endo Pharmaceuticals INC. | $980.30 | 2019-2024 | Xiaflex, Aveed, Edex |
| Abbvie INC. | $947.95 | 2019-2025 | |
| Urogen Pharma, INC. | $854.08 | 2020-2025 | Jelmyto |
| Antares Pharma, INC. | $825.67 | 2019-2024 | Xyosted, Nocdurna, Tlando |
| Progenics Pharmaceuticals, INC. | $654.28 | 2021-2025 | Pylarify |
| Novartis Pharmaceuticals Corporation | $542.10 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $407.34 | 2020-2024 | Lynparza |
| Amgen INC. | $390.94 | 2019-2023 | Prolia |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $360.83 | 2019-2025 | Adstiladrin |
| Merck Sharp & Dohme LLC | $289.28 | 2020-2025 | Welireg, Keytruda, Lynparza |
| Travere Therapeutics, INC. | $288.65 | 2019-2022 | |
| Myovant Sciences INC. | $228.29 | 2021-2022 | |
| Endo USA, INC. | $191.90 | 2024-2025 | Xiaflex, Aveed |
| Sun Pharmaceutical Industries INC. | $187.79 | 2019-2025 | Yonsa |
| Neotract INC. | $141.70 | 2020 | |
| Teleflex LLC | $131.59 | 2021-2023 | Urolift |
| Accord Healthcare, INC. | $120.14 | 2022-2024 | |
| Urovant Sciences INC | $93.32 | 2022 | |
| Rochester Medical Corporation | $93.26 | 2020-2022 | |
| Foundation Medicine, INC. | $77.85 | 2019-2022 | |
| Boston Scientific Corporation | $73.65 | 2019-2023 | Rezum Generator |
| Allergan, INC. | $72.34 | 2019-2020 | |
| Photocure INC | $65.28 | 2019-2021 | |
| Ambu INC. | $63.71 | 2022-2023 | |
| Halozyme INC | $58.27 | 2023 | |
| Genzyme Corporation | $55.56 | 2019-2023 | |
| Alnylam Pharmaceuticals INC. | $54.79 | 2022 | |
| C. R. Bard, INC. & Subsidiaries | $48.32 | 2023 | Bard Urinary Drainage Bag |
| Mission Pharmacal Company | $45.99 | 2019-2020 | |
| Bioprotect Medical, INC. | $39.38 | 2024 | Bioprotect Balloon Implant System |
| Innovation Technologies INC | $35.33 | 2022 | |
| Ethicon US, LLC | $31.98 | 2021-2022 | |
| Axonics, INC. | $28.75 | 2022-2023 | Axonics |
| Immunitybio, INC. | $27.86 | 2024-2025 | |
| Tempus Ai, INC | $26.39 | 2025 | Xt Cdx |
| Myriad Genetic Laboratories, INC. | $25.83 | 2021 | |
| Tolmar, INC. | $24.06 | 2023 | |
| Cycle Pharmaceuticals INC | $22.30 | 2024 | Tiopronin |
| Abc Home Medical Supply, INC. | $20.33 | 2025 | |
| Laborie Medical Technologies Corp. | $18.24 | 2024 | Endosheath Technology |
| Telix Pharmaceuticals | $17.70 | 2022 | |
| Metuchen Pharmaceuticals | $13.31 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $12.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Ratliff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.